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SUMMARY

We perform an immunogenomics analysis utilizing whole-transcriptome sequencing of 657 pediatric extracranial solid cancer samples representing 14 diagnoses, and additionally utilize transcriptomes of 131 pediatric cancer cell lines and 147 normal tissue samples for comparison. We describe patterns of infiltrating
immune cells, T cell receptor (TCR) clonal expansion, and translationally relevant immune checkpoints.
We find that tumor-infiltrating lymphocytes and TCR counts vary widely across cancer types and within
each diagnosis, and notably are significantly predictive of survival in osteosarcoma patients. We identify potential cancer-specific immunotherapeutic targets for adoptive cell therapies including cell-surface proteins,
tumor germline antigens, and lineage-specific transcription factors. Using an orthogonal immunopeptidomics approach, we find several potential immunotherapeutic targets in osteosarcoma and Ewing sarcoma
and validated PRAME as a bona fide multi-pediatric cancer target. Importantly, this work provides a critical
framework for immune targeting of extracranial solid tumors using parallel immuno-transcriptomic and -peptidomic approaches.
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INTRODUCTION
Pediatric malignancies remain the leading cause of diseaserelated death in children in the United States. While advances
in multidisciplinary treatment in the later parts of the 20th century
resulted in significant improvements in survival from pediatric
cancer, further progress over the last several decades has
been modest (Howlader et al., 2014). For most pediatric malignancies, especially solid tumors, survival remains poor for those
with relapsed or advanced disease.
Rarity and heterogeneity make pediatric cancers challenging to study and treat. Increasingly, there is a desire to
apply high-throughput analytical techniques to better characterize tumor’s molecular composition for precision therapeutics. Recently, two large next-generation sequencing studies
have helped to provide the landscape of the most common
mutational drivers across a range of pediatric cancers (Gröbner et al., 2018; Ma et al., 2018). While these studies form a
foundation for our molecular understanding of these malignancies, further work is needed to enable translation to the
clinic.
In recent years, immunotherapy has revolutionized the
treatment approach for an increasing number of adult cancer
types. These clinical breakthroughs have led to a heightened
interest in understanding the molecular basis for immunotherapy response. To further our understanding of the
immunogenomic landscape in pediatric malignancies, we performed an analysis of whole-transcriptome sequencing of 657
extracranial solid tumor specimens, representing 14 major
cancer diagnoses. A comprehensive analysis of the immunogenomic features of these tumors was performed including tumor microenvironment and immune infiltration pattern with
quantification, expression pattern of immune checkpoint
genes, tumor-specific genes, and intratumoral T cell receptor
(TCR) repertoire. We further provided orthogonal confirmation
of transcriptomics findings of immunotherapeutic targets by
evaluating the immunopeptidome of osteosarcoma and Ewing
sarcoma and demonstrated proof-of-concept in vitro and
in vivo cytotoxicity using a transcriptomics-informed adoptive
cell therapy (ACT) approach.
RESULTS
Whole-transcriptome sequencing analysis was performed on
657 tumor samples from 623 pediatric or young adult patients
diagnosed with an extra-cranial solid malignancy. In parallel,
RNA sequencing was performed on 131 commonly used cancer cell lines and 147 normal tissues representing 21 organs
(Table 1; Table S1A). Quality metrics of the sequencing data
are summarized in Table S1B and S1C. Fourteen different diagnoses, including sub-categories of neuroblastoma (NB;
MYCN amplified and not amplified) and rhabdomyosarcoma
(RMS; fusion positive and negative) were represented
(Table 1; Table S1A). Mirroring the relative disease incidence
of extracranial pediatric solid malignancies seen at our sites,
the majority of our cohort comprised one of four diagnoses:
neuroblastoma, rhabdomyosarcoma, Ewing sarcoma, and
osteosarcoma.
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Tumor immune microenvironment
To characterize the immune microenvironment in pediatric solid
tumors, we performed tumor profiling of infiltrating immune
cells using predefined immune gene sets, including CIBERSORT, immune, and stromal signatures where enrichment
scores for immune cell subtypes as well as a described overall
‘‘immune signature’’ in each tumor sample were calculated
(Newman et al., 2015; Yoshihara et al., 2013). First, we assessed enrichment scores for immune cell types and gene signatures in each tumor in the context of its tumor type (Figure 1A)
and observed diverse enrichment of immune signatures among
different types of tumors. There was a strong correlation between immune signature score and enrichment for all immune
cell subtypes (Figure 1A). Interestingly, there was a notable
clustering of fusion-driven malignancies such as Ewing sarcoma (EWS), fusion-positive RMS, synovial sarcoma (SS),
clear cell sarcoma of kidney (CCSK), and desmoplastic small
round cell tumor (DSRCT) as having low median infiltrating immune cell enrichments relative to other tumor types in the analysis. A notable exception to this pattern is alveolar soft part sarcoma (ASPS), which had the highest median immune signature
score among tumor types in our cohort despite being a fusion
driven malignancy. On the other hand, tumor types with the
highest relative median immune cell enrichment include diseases reported to have ‘‘complex’’ genomes including osteosarcoma (OS), melanoma (ML), and undifferentiated sarcoma
(UDS) (Figure 1A).
To compare pediatric tumors with adult malignancies, we performed a combined analysis of our cohort with publicly available
data from The Cancer Genome Atlas (TCGA). For the overall immune signature scores, all pediatric tumor subtypes displayed
modest or below median immune signature scores with corresponding modest CD8+ T cell enrichment relative to adult tumor
counterparts, with the notable exception of ASPS, which was the
only pediatric tumor to fall within the top quartile of median
enrichment (Figure 1B; Figure S1). Remarkably, ASPS displayed
the highest levels of human leukocyte antigen A (HLA-A) expression across all tumor types evaluated, including TCGA adult tumors (Figure S1). These results are notable in light of the recent
clinical observation that ASPS is one of the most clinically
responsive tumor types to checkpoint inhibitor therapy (Wilky
et al., 2019), and the association between expression of major
histocompatibility complex (MHC) molecules and efficacy of
checkpoint inhibitory therapies (Yuasa et al., 2017).
We next sought to evaluate the potential impact of tumor immune microenvironment on prognosis. For this analysis, we utilized the osteosarcoma patient cohort as outcomes data were
available for this subgroup in our cohort (Table S1D). Of note,
all tumor samples used for this analysis were taken from the primary tumor prior to any chemotherapy. Remarkably, similar to
our previously reported association between high immune cell
infiltrate enrichment and favorable prognosis in neuroblastoma
(Wei et al., 2018), we found that increased expression of immune
cell markers in the tumor microenvironment of these pre-treatment osteosarcoma tumors were significantly associated with
a more favorable outcome (Figures 1C and 1D). The associations
remain highly significant in cox-regression analysis to account
for metastatic status, indicating that the presence of CD8+
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Table 1. Sample cohort
Tumor samples
Diagnosis and subtype

Tumor count

Normal samples
Cell line count

Subtotal

Tissue type

Count

Alveolar soft part sarcoma (ASPS)

16

3

19

adrenal gland

8

Clear cell sarcoma of kidney (CCSK)a

16

0

16

bladder

8

Desmoplastic small round cell tumor (DSRCT)

40

0

40

cerebellum

10

Ewing sarcoma (EWS)b

79

43

122

cerebrum

8

Hepatoblastoma (HBL)

30

0

30

colon

9

Melanoma (ML)

6

0

6

heart

7

ileum

8

MYCN-amplified (NB.MYCN.A)

47

28

75

kidney

8

MYCN-not amplified (NB.MYCN.NA)

147

12

159

liver

8

Neuroblastoma (NB)c

Unknown (NB.Unknown)

12

0

12

lung

8

Osteosarcoma (OS)d

93

9

102

muscle

5

ovary

5

Fusion-negative (RMS-FN)

60

21

81

pancreas

6

Fusion-positive (RMS-FP)

38

12

50

prostate

9

Rhabdomyosarcoma (RMS)e

Synovial sarcoma (SS)

31

3

34

skeletal muscle

6

Teratoma

4

0

4

spleen

5

Undifferentiated sarcoma (UDS)

6

0

6

stomach

7

Wilms tumor (WT)

27

0

27

testis

7

Yolk sac tumor (YST)

5

0

5

Total

657

131

788

thyroid

1

ureter

7

uterus

7
147

a

Data are available in dbGaP: phs000466.
b
Data are available in dbGaP: phs000768.
c
Data are available in dbGaP: phs000467.
d
Data are available in dbGaP: phs000468.
e
Data are available in dbGaP: phs000720.

T cells in pre-treatment primary tumors is an independent predictor for patient outcome (Figure S2).
Immune checkpoint expression
Given the rapid development of checkpoint inhibitor therapy
across many tumor types, expression of immunoinhibitory molecules (e.g., CD274 or PD-L1) is of translational interest. Similar
to the immune cell infiltrate enrichment patterns, we observed
heterogeneity in the expression of immune checkpoint genes
both within and across tumor types (Figure 2A; Figure S3).
Consistent with its sensitivity to immune checkpoint blockade,
ASPS demonstrated the highest median expression of PD-L1
suggesting a dependency on this immune checkpoint for immune evasion (Figure 2A). To further evaluate for immune checkpoints that might be the most clinically relevant in our cohort, we
performed a correlation analysis between the expression of individual immune checkpoint genes and CD8+ T cell infiltrate
enrichment within cancer types to look for the co-occurrence
of these two features. Interestingly, we observed two patterns
of immune checkpoint expression correlates to CD8+ T cell infiltrate enrichment (Figure 2B). First was a cluster of cancer types
including NB, EWS, DSRCT, OS, and RMS in which the majority
of checkpoint genes evaluated are significantly correlated with

tumor-infiltrating CD8+ T cells (Spearman rank correlation >0.3;
adjusted p < 0.05). On the contrary, in the remaining tumor types
including ASPS, a much narrower set of immune modulating
genes are significantly associated with tumor-infiltrating CD8+
T cells (Figure 2B).
Expanding on our prior observations in neuroblastoma (Wei
et al., 2018), we noted appreciable differences in TIL enrichment
pattern (Figure 1A) and expressional levels of immune checkpoints between MYCN-not amplified (MYCN.NA) and MYCNamplified (MYCN.A) tumors (Figure 2A). To validate these findings at the protein level, we performed immunoprofiling using
multiplex NanoString digital spatial profiling technology on a
neuroblastoma tissue array containing 33 independent neuroblastoma tumors of which 9 were MYCN.A and 24 were
MYCN.NA (Wei et al., 2018). Consistent with the RNA
sequencing (RNA-seq) data, the protein-expression levels of
TIL infiltrate markers and immune checkpoints are generally
elevated in MYNC.NA tumors compared to MYCN.A tumors
(Figure 2C).
Despite disappointing early trials with immune checkpoint inhibitors, osteosarcoma has been proposed as a potentially immune responsive tumor due to favorable immunogenomic characteristics, including relatively high immune cell infiltration when
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Figure 2. Immune checkpoint expression in pediatric solid tumors
(A) Expression of selected immune checkpoint genes across tumor types. Dots represent the median expression for each cancer type.
(B) Correlation of immunomodulatory gene expression and CD8+ T cell infiltrate. Fill indicates significant association (Spearman rank correlation >0.3; adjusted
p < 0.05) within that cancer type. Highlighted genes in the blue font represent targets of antibody therapies approved by FDA or currently in clinical trial.
(C) Protein expression of an immune gene panel on an independent neuroblastoma tissue array (Wei et al., 2018) using a multiplex protein detection assay reveal
consistent findings of differential expression of immune cell markers between MYCN-amplified (MYCN.A) and MYCN-not amplified (MYCN.NA) tumors. The scale
bar represents Z-scored standardized protein-expression level.

compared to other pediatric cancer types. We then selected osteosarcoma to further validate the presence of immune cell types
and immune checkpoint expression as predicted by RNA-seq.
Multiplexed immunohistochemistry was performed for a panel
of immune markers in an independent cohort of 25 osteosarcoma tumors. Consistent with the RNA-seq prediction and the
previous findings in a subset of TARGET osteosarcoma cohort
(Wunder et al., 2020), there were robust infiltrating T cells
(markers CD3, CD8) and M2 macrophages (CD163), with moderate PD-L1 expression in these osteosarcoma samples (Figure S4). On the other hand, relative to other pediatric solid tumor
types, we observed osteosarcoma to exhibit pronounced
expression of additional immunosuppressive molecules particularly TGFB1 and CSF1R, where median expression was the highest among all tumor types in the study cohort (Figure S3).

T cell receptor repertoire
To further characterize the immunologic landscape of pediatric solid tumors, we performed an analysis of the T cell receptor (TCR) repertoire utilizing a computational method for de
novo assembly of hypervariable region sequences from complementary-determining region 3 (CDR3) (Li et al., 2016). In
total, we identified 35,897 unique T cell receptor beta-chain
(TCR-b)-CDR3 sequences across our tumor cohort (Figure 3A;
Table S2). Of note, MYCN-not-amplified NB and ASPS had the
highest median TCR-b counts among the tumor types studied,
in keeping with their responsiveness to immune therapy. The
CDR3 sequences had lengths ranging from 6 to 25 amino
acids with a median length of 14 (Figure S5A). The sequence
patterns for the most frequent 14-amino-acid CDR3 sequence
were very similar to that previously reported across a large

Figure 1. Tumor immune microenvironment of pediatric solid tumors
(A) Global pattern of enrichment of various immune signatures across cancer types. Tumor types with a sample size of >5 are shown. The heatmap corresponds to
the percentage of tumors with a positive enrichment score for the immune cell subtype by ssGSEA.
(B) Distribution of immune signature enrichment scores across cancer types included in this study (colored) as compared to adult tumor samples in the TCGA
project (gray).
(C and D) Kaplan-Meier (KM) plots of overall survival demonstrate that patients with tumors of high immune score (C) or high CD8+ T cell score (D) are significantly
associated with a favorable prognosis in the osteosarcoma cohort where outcome data are available.

Cell Reports 37, 110047, November 23, 2021 5

ll
OPEN ACCESS

A

Article
B

D
C

Figure 3. Intra-tumoral T cell receptor b (TCR-b) repertoire identified using RNA-seq data in pediatric solid tumors
(A) Number of unique complementary-determining region 3 (CDR3) detected in each tumor. Red bars represent median for each cancer type.
(B) Kaplan-Meier analysis of available outcome data in the osteosarcoma cohort demonstrates that patients with a high TCR-b count are significantly associated
with favorable outcome (p < 0.01).
(C) In order to investigate T cell clone expansion in individual tumors, TCR-b clones are ranked by their abundance on the x axis and the normalized clone count is
plotted on the y axis. Each line represents all TCR-b clones detected in a single tumor and clearly shows evidence of high clonal expansion of some TCRs.
(D) Clonal expansion of TCR-bs. Each dot represents a TCR-b clone in a tumor sample. The highlighted region depicts expanded TCR-b clones as evidenced by
high normalized clone count (>99th percentile) and high relative contribution to the total intra-tumoral TCR-b count (>1%). The accompanying table details the
percentage of tumors with R1 clonally expanded TCR-b. *Total tumor/patient count and calculated percentages include all patients in the study cohort.

set of adult cancers (TCGA) as well as in the peripheral blood
of healthy donors (Figure S5) (Li et al., 2016; Warren et al.,
2011).
We next compared TCR sequences identified within our tumor
cohort to those identified across the TCGA database (Li et al.,
2016), to those identified in normal tissues from our study cohort,
and to those reported in two healthy donor population databases
(Shugay et al., 2018; Warren et al., 2011) (Table S2; Figure S5F).
Of the 35,897 total TCRs identified across our tumor cohort,
29,381 (84.7%) were unique to a single tumor and not present
in the comparator databases, 5,327 (15.3%) overlapped with
one of the healthy adult databases or normal tissues. Of note,
out of 194 shared TCR sequences in 2 or more tumors, 165, represented by unique protein sequences, were shared in 2 or more
patients within our cohort and not present in the comparator
healthy population databases, which may represent tumor targeting TCRs (Table S2; Figure S5F).
We evaluated the potential impact of intra-tumoral TCR
burden (measured as TCR counts) on outcome in the OS cohort
where clinical data were available. Similar to our analysis of immune score and CD8+ T cell infiltrate enrichment, we found
that patients with a high TCR clone burden in these pre-treat-
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ment samples were significantly associated with a more favorable prognosis (Figure 3B), which was independent of the metastatic status of the patient (Figure S2).
To evaluate for possible clonal expansion of TCRs, we determined the abundance of each CDR3 clone (counts/million) as
well as the relative contribution of each TCR clone to the total
TCR counts found in each tumor. Indeed, we noted several tumors that had evidence of high intra-tumoral TCR burden with
varying degrees of TCR diversity (Figure 3C). When quantifying
expanded TCR clones as defined by both high expression
(>99th percentile) and high relative contribution to total intra-tumoral TCR count in a given tumor (>1%), we observed 36/623
(5.8%) of patients (range 0%–26.7% per cancer type) having a
tumor that met our criteria for intra-tumoral clonal T cell expansion (Figure 3D). Interestingly, ASPS and OS, which we also
identified as having high relative enrichment of immune cell infiltrate and high median immune signature scores, were found to
have the highest percentage of expanded intra-tumoral TCR
clones, in 26.7% and 22.0% of patients, respectively. We did
not find evidence of TCR clonal expansion in any tumor samples
from MYCN-amplified NB, DSRCT, CCSK, ML, or WT in our
cohort.
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Expression of cell-surface proteins, transcription
factors, and tumor germline antigens
To discover potential targets for immunotherapy, we performed
differential gene-expression analysis comparing each cancer
type to 147 normal tissue samples (excluding testis and ovary)
using stringent criteria of p % 0.00001 with a fold change R16
compared to normal. We first identified cancer-specific cell-surface genes that may be targets for Chimeric Antigen Receptor
T cell (CART) or antibody-based therapies. This approach identified 107 cell-surface genes (Figure 4A; Table S3A), with notable
findings including GPC2, ALK, and FGFR4, which are being
developed in preclinical or clinical studies as targets for CART
therapies by our group and others (Richards et al., 2018). To
identify other genes that may be a potential source of immunoreactivity for adoptive cellular therapy (ACT), we also performed a
similar analysis for transcription factors and tumor germline antigens (TGAs) to identify those that are robustly expressed in tumors but show low or absent expression in normal tissues. We
identified 88 transcription factors, many of which have been
described previously as part of the core regulatory transcription
factor circuitry in specific cancer types, such as PHOX2B,
TWIST1, and ISL1 in neuroblastoma (Durbin et al., 2018; Selmi
et al., 2015); MYOD1 and MYOG in rhabdomyosarcoma (Gryder
et al., 2017); NR0B1 in Ewing sarcoma (Kinsey et al., 2006) (Figure 4B; Table S3B). For TGAs, we identified 43 genes, including
those that are currently under clinical investigation as ACT targets such as NY-ESO-1 (CTAG1A) in synovial sarcoma (D’Angelo et al., 2018b), and PRAME in a number of histologic types
(Gutzmer et al., 2016; Luk et al., 2018) (Figure 4C; Table S3C).
Although the median expression of these potential immunotherapeutic targets was high in various cancer types, their expression was not uniform across all tumors (Figure 4D).
To evaluate whether currently available cell line models exhibit
expression of cancer-specific potential immunotherapy targets
congruent to that observed in patient tumors, we evaluated transcriptome sequencing of a panel of 131 commonly utilized cell
lines. For top hits GPC2, FOXM1, and PRAME, cell line expression was similar to the corresponding tumors of the same histology (Figure S6A). More broadly, we report the expression data
for commonly used cell lines representative of their respective
cancers for ASPS, EWS, NB.MYCN.A, NB.MYCN.NA, OS,
RMS.FP, RMS.FN, and SS, enabling researchers to identify suitable cell lines for further study based on gene-expression
level of specific immune targets (Table S3; https://omicsoncogenomics.ccr.cancer.gov/cgi-bin/JK).
Of tumor germline antigens, we identified PRAME as a potential multi-pediatric cancer target, expressed in many of the tumor
types but showing minimal to no expression in all normal organs
except testes and ovaries (Figures 4C and 4D). High protein
expression of PRAME in neuroblastoma (Oberthuer et al.,
2004) and osteosarcoma (Tan et al., 2012) have previously
been reported. To validate expression in additional tumor types,
we performed immunohistochemistry (IHC) of PRAME on an independent panel of pediatric solid tumors and patient derived
xenografts (PDXs), which confirmed its robust expression in
7/12 (58%) samples (Figure S6D). Representative images are
shown for OS, EWS, fusion-negative RMS, and control tissues
(Figure 4E; Figure S6).

Identification of targetable tumor antigens in OS and
EWS using immunopeptidome
To further validate our RNA-seq findings of cancer-specific antigens and understand how these antigens might be presented
by MHC class I complexes, we performed immunopeptidome
(HLA-Ligandome) analysis using MHC class I immunoprecipitation (IP), peptide elution, and identification using LC-MS/MS on
HLA*A2:01 positive cell lines (Figure S7). We focused on OS
and EWS as these are among the most common pediatric sarcomas and remain a significant therapeutic challenge for metastatic disease. Integration of our transcriptomic and immunopeptidomic analyses revealed high-affinity peptides derived
from tumor-associated genes such as PRAME, PBK, and several
MAGE gene family genes (Table 2). Several of these MHC class I
peptides were also observed in immune-responsive adult malignancies and have been successfully targeted using engineered
T cells with adoptive cell transfer (Table 2; Table S4).
Among the peptides identified, we identified two HLA*A2:01
restricted peptides (ALLPSLSHC, SLLQHLIGL) derived from the
PRAME protein (Table 2; Table S4). As a proof of concept for targeting PRAME, we tested a previously reported TCR targeting the
PRAME HLA*A2:01 peptide SLLQHLIGL (Amir et al., 2011). Healthy
donor T cells expressing the PRAME TCR showed cytotoxicity and
cytokine production when co-cultured with U2OS (Figure S7), an
osteosarcoma cell line that we found to present SLLQHLIGL on
HLA*A2:01. To improve activity and specificity, we modified the
PRAME TCR by swapping the TCR constant domains with the
murine equivalent and adding cysteine linkers to improve exogenous TCR-a-TCR-b pairing (Cohen et al., 2006, 2007) (herein called
murPRAME-TCR). We next engineered SAOS2 (OS) and TC32
(EWS) cells expressing a reporter luciferase:mCherry (negative
control) or luciferase:PRAME (positive control) (Figure 5A).
SAOS2 and TC32 cell lines were selected for their high expression
of HLA*A2:01 (Figure S7A) and lack of endogenous PRAME
expression, allowing us to test the specificity of the murPRAMETCR. Co-culture of these lines with the murPRAME-TCR cells
had no significant effect on either control cell line expressing luciferase:mCherry (Figure 5B, top). However, we observed significant
cytotoxicity against SAOS2 and TC32 expressing PRAME from
murPRAME-TCR T cells (Figure 5B, bottom).
Last, we tested whether murPRAME-TCR T cells could have
therapeutic potential as an adoptive cell therapy in vivo using
an aggressive metastatic EWS mouse model with intravenous
delivery of PRAME-expressing TC32 cells (Figure 5C). After
engraftment, mice were randomized and treated with vehicle
(Hank’s balanced salt solution [HBSS]), untransduced T cells
(UTD), or murPRAME-TCR-transduced T cells (Figure 5C). Saline
and UTD-treated mice displayed rapid, disseminated tumor
growth, whereas mice treated with murPRAME-TCR T cells
had a significant and durable regression of their tumors and prolonged survival (Figures 5D–5F). Altogether, these data demonstrate that PRAME can be effectively targeted as an adoptive
TCR cell therapy in these in vitro and in vivo models.
DISCUSSION
Here, we report one of the largest and most comprehensive immune-transcriptomic landscape of extracranial pediatric solid
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Figure 4. Tumor-specific gene expression
(A–C) Tumor-specific gene expression including (A) cell-surface proteins, (B) transcription factors, and (C) tumor germline antigens. Fill indicates that the gene is
overexpressed in the corresponding cancer type relative to normal tissues and has minimal expression in vital organs.
(D) mRNA expression of top genes for each category in each cancer type, vital organs, testes, ovary, and other normal tissues. Dots represent the median
expression for each cancer type.
(E) Representative PRAME immunohistochemistry in Ewing sarcoma and osteosarcoma demonstrates a robust expression of PRAME protein in tumor cells. H&E,
hematoxylin and eosin stain.
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Table 2. Summary table of OS and EWS MHC class I peptides

Gene
PRAME
MAGEA1

Peptide

HLA allele
specificity

Predicted
Percentile affinity
rank
(IC50 nM) Other cancers presenting same peptide

ALLPSLSHC

HLA-A*02:01 2.72

467.3

melanoma (Gloger et al., 2016)

SLLQHLIGL

HLA-A*02:01 0.12

9.9

melanoma (Gloger et al., 2016; Bassani-Sternberg et al., 2016)

HLA-A*02:01 0.05

5.9

Melanoma (Bassani-Sternberg et al., 2016; Pritchard et al., 2015)

MAGEA1/A4/A8 AETSYVKVL

KVLEYVIKV

HLA-B*44:02 0.09

72.4

melanoma (Pritchard et al., 2015), breast cancer (Ternette
et al., 2018)

MAGEB2

GVYDGEEHSV

HLA-A*02:01 2.44

386.5

chronic myeloid leukemia (Hassan et al., 2013)

MAGED2

NADPQAVTM

HLA-C*05:01 0.08

172.1

breast cancer (Ternette et al., 2018; Rozanov et al., 2018), chronic
lymphocytic leukemia (Nelde et al., 2018)

PBK

SYQKVIELF

HLA-C*07:04 0.65

7398.1

breast cancer (Ternette et al., 2018; Rozanov et al., 2018),
glioblastoma (Shraibman et al., 2019), melanoma (Pritchard et al.,
2015; Bassani-Sternberg et al., 2017)
none reported

KREMEN2

ALGPPGAAL

HLA-A*02:01 2.80

494.5

ULBP3

LLFDWSGTGRA

HLA-A*02:01 2.74

473.5

colon cancer (Bassani-Sternberg et al., 2015)

LLFDWSGTGRADA HLA-A*02:01 2.81

498.4

colon cancer (Bassani-Sternberg et al., 2015)

IGF2BP3

KIQEILTQV

HLA-A*02:01 0.23

17.7

melanoma (Gloger et al., 2016; Jensen et al., 2018), chronic
myeloid leukemia (Jensen et al., 2018), colon cancer (Murphy
et al., 2019), breast cancer (Ternette et al., 2018)

KIF20b

AEIEDIRVL

HLA-B*44:02 0.12

94.8

melanoma (Koumantou et al., 2019), chronic lymphocytic
leukemia (Nelde et al., 2018)

A summary table of high-affinity peptides in OS and EWS cells. Peptide percentage ranks and predicted HLA affinities were calculated using NetMHC
(Jurtz et al., 2017) with sequencing-identified HLA allele variants present in the corresponding cell line.

tumors, with data derived from 788 malignant samples including
657 solid tumor samples across 14 diagnoses from 623 pediatric
and young adult patients and 131 commonly used cancer cell
lines. Success with checkpoint inhibitor therapy in many cancer
types has led to an increased desire to understand the tumor-immune microenvironment interactions. Toward this end, we
describe the immunogenomic landscape of our cohort of pediatric solid malignancies including tumor-infiltrating lymphocyte
composition, cancer germline antigen and cell-surface protein
expression, immune checkpoint expression, and T cell receptor
repertoire. Notably, we observed a substantial degree of intrahistologic variance in all immunogenomic features evaluated,
suggesting that histology alone may be insufficient for immunotherapeutic selection or trial design in these diseases. Broadly,
we note a generally lower level of immune cell infiltration in
most pediatric solid tumors compared to common adult tumors,
with a notable exception of ASPS.
A high tumor mutation burden (TMB) has been associated with
clinical response to checkpoint inhibition (Chan et al., 2019). Pediatric cancers typically have a low somatic mutation burden
relative to common adult cancers (Gröbner et al., 2018; Ma
et al., 2018); however, we have previously reported that the
TMB in relapsed samples can increase two to three times
compared to their primary tumors (Chang et al., 2016; Eleveld
et al., 2015). Nonetheless, some cancers with low TMB such
as clear cell renal cell carcinoma show a strong intratumor immune-related cytolytic activity and prominent immune infiltrate,
findings that may be related to their clinical responsiveness to
immune checkpoint inhibitors (Miao et al., 2018). These results
emphasize that TMB may not be the only source of immunogenic

triggers. Notably, ASPS, a disease recently found to be highly
responsive to immune checkpoint inhibition (Wilky et al., 2019),
was observed in our study to be among the highest degree of
baseline TIL infiltrate despite being a low-TMB fusion-driven malignancy. Intra-tumoral T cell receptor clonality has been associated with clinical outcomes in metastatic cancers (Tumeh et al.,
2014) and in the setting of immunotherapies (Zhang et al., 2020).
Utilizing TCR prediction methodology to assess intra-tumoral
clonotypes, we were able to demonstrate cases of robust expansion of TCR clones in 5.8% of patients, occurring at the highest
frequency in ASPS and OS tumors, which suggests that a subset
of pediatric solid tumors are more primed for immunotherapeutic
interventions.
A striking finding from this study is the identification of high
median T cell infiltration in OS relative to other pediatric solid tumors and a significant correlation between immune cell infiltrate
and patient survival. We further show that CD8+ T cell infiltration
is independent of metastasis, a known predictor of poor outcomes. Prior reports have also demonstrated robust immune
cell infiltrate and PD-L1 expression in a subset of OS, though
studies have conflicted results regarding the correlation between
these immunologic features and patient outcomes (Thanindratarn et al., 2019; Wunder et al., 2020). In contrast to these
immunologically favorable observations, we also observed pronounced expression of many additional immune inhibitory
signaling molecules in osteosarcoma tumors, including TGFB1
and CSF1R. Our findings are congruent with a previous analysis
in osteosarcoma that utilizes a partially overlapping osteosarcoma cohort in the Therapeutically Applicable Research to
Generate Effective Treatments (TARGET) dataset (Wu et al.,
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Figure 5. Specific anti-tumor activity of engineered T cells targeting a PRAME MHC class 1 peptide
(A) Structure of engineered PRAME TCR and schema for testing the specificity and efficacy of murPRAME-TCR T cells.
(B) In vitro co-culture of T cells with reporter cell lines at different effector:tumor (E:T) ratios. Luminescence was measured after 24 h of co-culture and reported as
mean ± SEM (n = 3); **p < 0.01, ***p < 0.001.
(C) Schema for treating metastatic EWS xenograft model with murPRAME-TCR T cells.
(D) Bioluminescence images of TC32-Luc:PRAME cells after IV injection and treatment with vehicle or T cells.
(E) Quantification of bioluminescence imagining reported as mean ± SEM (n = 8 per group). p values of UTD versus murPRAME-TCR mice displayed as *p < 0.05,
**p < 0.01.
(F) Kaplan-Meier analysis of mouse survival using log-rank test (n = 8 per group).

2020), which reported OS to be near the 50th percentile
compared to adult TCGA tumor types based on the rank order
of tumors by median immune score, and multiple immune inhibitory pathways were also noted to be active. Given the limited efficacy of immune checkpoint inhibitor monotherapy for OS in
clinical trials to date (D’Angelo et al., 2018a; Merchant et al.,
2016; Tawbi et al., 2017), these results suggest potential coinhibitory pathways in this disease that would make rationale targets for combination immunotherapies. (Song et al., 2021; Wu
et al., 2020).
In addition to checkpoint blockade, directed immune targeting
of tumor expressed antigens is another broad strategy for cancer
immunotherapy. Toward this goal, we provide an overview of the
expressed antigens in our cohort that are predicted to be the
most translationally relevant due to differential expression from
normal tissues. Our results confirm many of the tumor germline
antigens that are in current clinical development, as well as a
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broad landscape of additional targets. As proof of concept of utilizing transcriptomics and immunopeptidomic approaches, we
identified PRAME as an immune target, a highly differentially expressed protein with its peptide presented on the cell surface in
the context of HLA-A2, the most frequent HLA allele in humans.
Despite minor nonspecific cytotoxicity, which is commonly
observed with infusion of UTD, our modified PRAME TCR-transduced T cells showed significantly higher in vitro activity in both
OS and EWS cell line models, as well as significant potency
in vivo in a metastatic EWS mouse model. Importantly, our
data suggest that PRAME may be a broad, multi-cancer immunotherapy target in pediatric extracranial solid malignancies,
similar to efforts in hematologic malignancies where clinical trials
are underway (e.g., NCT02494167 and NCT02203903).
In summary, we describe here, one of the largest to date, transcriptomics-derived immunogenomics surveys of extracranial
pediatric solid malignancies. We find significant correlations
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between immunogenomic features, such as immune cell infiltration, especially intra-tumoral clonal T cell infiltration, with patient
survival. We provide a landscape of expressed tumor antigens
that are most likely to be amenable to immunotherapeutic targeting. We further provide orthogonal confirmation of transcriptomic findings by evaluating the immunopeptidome of osteosarcoma and demonstrate proof of concept in vitro cytotoxicity
using a transcriptomics-informed ACT approach. This work provides a critical framework for immune targeting of low mutational
burden extracranial solid tumors using transcriptome
profiling data. Furthermore, a companion gene-expression database (https://omics-oncogenomics.ccr.cancer.gov/cgi-bin/JK)
derived from this study with outcome data including overall
and event-free survival for osteosarcoma and neuroblastoma allows further exploration of this rich dataset. Finally, we report on
an engineered TCR against PRAME can be developed for ACT
immunotherapy for patients with pediatric solid tumors with
HLA-A*02.
Limitations of the study
A limitation of our study is the availability of clinical outcomes
data in only two (NB and OS) tumor types studied. Despite
this, we have reported a consistent association between high immune infiltrate and immune signatures score and favorable prognosis in both osteosarcoma and neuroblastoma (Wei et al.,
2018), a result that remains significant even when accounting
for metastatic disease status. Despite the consistency observed
in these two tumor types, we cannot evaluate whether this is a
universal finding among pediatric solid tumor types or specific
to these two diseases.
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I., López-Larrea, C., Hilf, N., Kuttruff, S., Song, C., et al. (2019). Identification of
Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and
Plasma. Mol. Cell. Proteomics 18, 1255–1268.
Shugay, M., Bagaev, D.V., Turchaninova, M.A., Bolotin, D.A., Britanova, O.V.,
Putintseva, E.V., Pogorelyy, M.V., Nazarov, V.I., Zvyagin, I.V., Kirgizova, V.I.,
et al. (2015). VDJtools: Unifying Post-analysis of T Cell Receptor Repertoires.
PLoS Comput. Biol. 11, e1004503.
Shugay, M., Bagaev, D.V., Zvyagin, I.V., Vroomans, R.M., Crawford, J.C.,
Dolton, G., Komech, E.A., Sycheva, A.L., Koneva, A.E., Egorov, E.S., et al.
(2018). VDJdb: a curated database of T-cell receptor sequences with known
antigen specificity. Nucleic Acids Res. 46 (D1), D419–D427.
Song, Y.J., Xu, Y., Deng, C., Zhu, X., Fu, J., Chen, H., Lu, J., Xu, H., Song, G.,
Tang, Q., and Wang, J. (2021). Gene Expression Classifier Reveals Prognostic
Osteosarcoma Microenvironment Molecular Subtypes. Front. Immunol. 12,
623762.
Sunshine, J.C., Nguyen, P.L., Kaunitz, G.J., Cottrell, T.R., Berry, S., Esandrio,
J., Xu, H., Ogurtsova, A., Bleich, K.B., Cornish, T.C., et al. (2017). PD-L1
Expression in Melanoma: A Quantitative Immunohistochemical Antibody
Comparison. Clin. Cancer Res. 23, 4938–4944.
Tan, P., Zou, C., Yong, B., Han, J., Zhang, L., Su, Q., Yin, J., Wang, J., Huang,
G., Peng, T., and Shen, J. (2012). Expression and prognostic relevance of
PRAME in primary osteosarcoma. Biochem. Biophys. Res. Commun. 419,
801–808.
Tawbi, H.A., Burgess, M., Bolejack, V., Van Tine, B.A., Schuetze, S.M., Hu, J.,
D’Angelo, S., Attia, S., Riedel, R.F., Priebat, D.A., et al. (2017). Pembrolizumab
in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre,
two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 18, 1493–
1501.
Teicher, B.A., Polley, E., Kunkel, M., Evans, D., Silvers, T., Delosh, R., Laudeman, J., Ogle, C., Reinhart, R., Selby, M., et al. (2015). Sarcoma Cell Line
Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA Expression. Mol. Cancer Ther. 14, 2452–
2462.
€ller, J., Anderson, A.P., Nicastri, A.,
Ternette, N., Olde Nordkamp, M.J.M., Mu
Hill, A.V.S., Kessler, B.M., and Li, D. (2018). Immunopeptidomic Profiling of
HLA-A2-Positive Triple Negative Breast Cancer Identifies Potential Immunotherapy Target Antigens. Proteomics 18, e1700465.

Richards, R.M., Sotillo, E., and Majzner, R.G. (2018). CAR T Cell Therapy for
Neuroblastoma. Front. Immunol. 9, 2380.

Thanindratarn, P., Dean, D.C., Nelson, S.D., Hornicek, F.J., and Duan, Z.
(2019). Advances in immune checkpoint inhibitors for bone sarcoma therapy.
J. Bone Oncol. 15, 100221.

Robinson, M.D., McCarthy, D.J., and Smyth, G.K. (2010). edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139–140.

Tran, N.H., Qiao, R., Xin, L., Chen, X., Liu, C., Zhang, X., Shan, B., Ghodsi, A.,
and Li, M. (2019). Deep learning enables de novo peptide sequencing from
data-independent-acquisition mass spectrometry. Nat. Methods 16, 63–66.

Rozanov, D.V., Rozanov, N.D., Chiotti, K.E., Reddy, A., Wilmarth, P.A., David,
L.L., Cha, S.W., Woo, S., Pevzner, P., Bafna, V., et al. (2018). MHC class I
loaded ligands from breast cancer cell lines: A potential HLA-I-typed antigen
collection. J. Proteomics 176, 13–23.

Tumeh, P.C., Harview, C.L., Yearley, J.H., Shintaku, I.P., Taylor, E.J., Robert,
L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014). PD-1
blockade induces responses by inhibiting adaptive immune resistance. Nature
515, 568–571.

Saletta, F., Vilain, R.E., Gupta, A.K., Nagabushan, S., Yuksel, A., Catchpoole,
D., Scolyer, R.A., Byrne, J.A., and McCowage, G. (2017). Programmed Death-

Warren, R.L., Freeman, J.D., Zeng, T., Choe, G., Munro, S., Moore, R., Webb,
J.R., and Holt, R.A. (2011). Exhaustive T-cell repertoire sequencing of human

Cell Reports 37, 110047, November 23, 2021 13

ll
OPEN ACCESS

Article

peripheral blood samples reveals signatures of antigen selection and a directly
measured repertoire size of at least 1 million clonotypes. Genome Res. 21,
790–797.

teosarcoma and soft-tissue sarcomas with an immune infiltrate express PDL1: relation to clinical outcome and Th1 pathway activation. OncoImmunology
9, 1737385.

Wei, J.S., Kuznetsov, I.B., Zhang, S., Song, Y.K., Asgharzadeh, S., Sindiri, S.,
Wen, X., Patidar, R., Najaraj, S., Walton, A., et al. (2018). Clinically Relevant
Cytotoxic Immune Cell Signatures and Clonal Expansion of T-Cell Receptors
in High-Risk MYCN-Not-Amplified Human Neuroblastoma. Clin. Cancer Res.
24, 5673–5684.

Yoshihara, K., Shahmoradgoli, M., Martı́nez, E., Vegesna, R., Kim, H., TorresGarcia, W., Treviño, V., Shen, H., Laird, P.W., Levine, D.A., et al. (2013). Inferring tumour purity and stromal and immune cell admixture from expression
data. Nat. Commun. 4, 2612.

Wilky, B.A., Trucco, M.M., Subhawong, T.K., Florou, V., Park, W., Kwon, D.,
Wieder, E.D., Kolonias, D., Rosenberg, A.E., Kerr, D.A., et al. (2019). Axitinib
plus pembrolizumab in patients with advanced sarcomas including alveolar
soft-part sarcoma: a single-centre, single-arm, phase 2 trial. Lancet Oncol.
20, 837–848.
Wu, C.C., Beird, H.C., Andrew Livingston, J., Advani, S., Mitra, A., Cao, S.,
Reuben, A., Ingram, D., Wang, W.L., Ju, Z., et al. (2020). Immuno-genomic
landscape of osteosarcoma. Nat. Commun. 11, 1008.
Wunder, J.S., Lee, M.J., Nam, J., Lau, B.Y., Dickson, B.C., Pinnaduwage, D.,
Bull, S.B., Ferguson, P.C., Seto, A., Gokgoz, N., and Andrulis, I.L. (2020). Os-

14 Cell Reports 37, 110047, November 23, 2021

Yuasa, T., Masuda, H., Yamamoto, S., Numao, N., and Yonese, J. (2017). Biomarkers to predict prognosis and response to checkpoint inhibitors. Int. J.
Clin. Oncol. 22, 629–634.
Zhang, J., Mardis, E.R., and Maher, C.A. (2017). INTEGRATE-neo: a pipeline
for personalized gene fusion neoantigen discovery. Bioinformatics 33,
555–557.
Zhang, J., Ji, Z., Caushi, J.X., El Asmar, M., Anagnostou, V., Cottrell, T.R.,
Chan, H.Y., Suri, P., Guo, H., Merghoub, T., et al. (2020). Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non-Small Cell Lung Cancer. Clin.
Cancer Res. 26, 1327–1337.

ll
OPEN ACCESS

Article
STAR+METHODS
KEY RESOURCES TABLE

Reagent or resource

Source

Identifier

Antibodies
Anti-CD3

Leica Biosystems

Clone PS1

Anti-CD8

Cell Marque

Clone C8144B

Anti-CD163

Leica Biosystems

Clone Novasasta10D6

Anti-PD-L1

Spring Bioscience

Clone SP142

Anti-PD-L1 isotype control

Spring Bioscience

Clone SP137

Pan-reactive for MHC class I, clone W6/32

BioLegend

Cat. 311405

Anti-HLA*A2, clone BB7.2

BioLegend

Cat. 343308

Anti-FLAG, clone L5

BioXcell

Cat. 637304

Anti-tEGFR

BioLegend

Cat. 352903

Anti-PRAME

Abcam

Cat. ab219650

TruSeq Stranded mRNA library Prep kits

Illumina

https://www.illumina.com/products/
by-type/sequencing-kits/libraryprep-kits/truseq-stranded-mrna.html

TruSeq Stranded Total RNA

Illumina

https://www.illumina.com/products/
by-type/sequencing-kits/libraryprep-kits/truseq-stranded-totalrna.html

XenoLight D-Luciferin Potassium Salt

Perkin Elmer

Cat. 122799-5

Nanostring

https://www.nanostring.com/
products/geomx-digital-spatialprofiler/geomx-dsp-overview/

Chemicals, peptides, and recombinant proteins

Critical commercial assays
Nanostring GeoMx Digital Spatial Profiler (DSP)

V-PLEX human cytokine assay

Meso Scale Diagnostics

Cat. K151AOH-2

Steady-Gloâ Luciferase Assay System

Promega

E2520

Deposited data
dbGAP phs001928 for pediatric cancers

This study

https://www.ncbi.nlm.nih.gov/gap/

dbGaP phs000466 for CCSK

(Gooskens et al., 2015)

https://www.ncbi.nlm.nih.gov/gap/

dbGaP phs000467 for NBL

(Wei et al., 2018)

https://www.ncbi.nlm.nih.gov/gap/

dbGaP phs000468 for OS

https://ocg.cancer.gov/
programs/target/projects/
osteosarcoma

https://www.ncbi.nlm.nih.gov/gap/

dbGaP phs000720 for RMS

(Shern et al., 2014)

https://www.ncbi.nlm.nih.gov/gap/

dbGaP phs000768 for EWS

(Brohl et al., 2014)

https://www.ncbi.nlm.nih.gov/gap/

dbGaP phs001052 for Omics study

(Chang et al., 2016)

https://www.ncbi.nlm.nih.gov/gap/

Gene expression of neuroblastoma cell lines;
GEO GSE89413

(Harenza et al., 2017)

https://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc=GSE89413

Immunopeptidomes data osteosarcoma cell lines

https://www.ebi.ac.uk/pride

Accession: PXD017130

Experimental models: Cell lines
ASPS4c159

This study

N/A

CC-A

This study

N/A

FUUR1

This study

N/A

NCIEWS5000

This study

N/A

6647

This study

N/A

A673

This study

N/A
(Continued on next page)
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Source

Identifier

CHLA258

This study

N/A

CHLA352

This study

N/A

CHP100L

This study

N/A

SKES1

This study

N/A

SKNLO

This study

N/A

SKNMC

This study

N/A

TC106

This study

N/A

TC138

This study

N/A

TC167

This study

N/A

TC177

This study

N/A

TC215

This study

N/A

TC233

This study

N/A

TC244

This study

N/A

TC248

This study

N/A

TC253

This study

N/A

TC32

This study

N/A

TC487

This study

N/A

TC4C

This study

N/A

TTC466

This study

N/A

TTC475

This study

N/A

TTC547

This study

N/A

CHP134

This study

N/A

GILIN

This study

N/A

IMR32

This study

N/A

IMR5

This study

N/A

KCNR

This study

N/A

LAN1

This study

N/A

LAN5

This study

N/A

NB1691

This study

N/A

SKNBE2

This study

N/A

SKNDZ

This study

N/A

NBEB

This study

N/A

SHSY5Y

This study

N/A

SKNAS

This study

N/A

SKNFI

This study

N/A

SKNSH

This study

N/A

BIRCH

This study

N/A

CT-10

This study

N/A

CTR

This study

N/A

RD

This study

N/A

RH1

This study

N/A

RH18

This study

N/A

RMS559

This study

N/A

TTC-442

This study

N/A

TTC-516

This study

N/A

CW9109

This study

N/A

JR

This study

N/A

MP4

This study

N/A

NCI-ARMS1

This study

N/A
(Continued on next page)
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Source

Identifier

NCI-RMS-052

This study

N/A

RH28

This study

N/A

RH30

This study

N/A

RH4

This study

N/A

RH41

This study

N/A

RH5

This study

N/A

ASPS1

This study

N/A

CHLA10

This study

N/A

CHLA25

This study

N/A

CHLA32

This study

N/A

CHLA9

This study

N/A

ES8

This study

N/A

RDES

This study

N/A

TC71

This study

N/A

HOS

This study

N/A

SAOS2

This study

N/A

SJSA1

This study

N/A

U2OS

This study

N/A

Hs729

This study

N/A

RH36

This study

N/A

SKNEP1

This study

N/A

SKPNETLI

This study

N/A

TC240

This study

N/A

7556

This study

N/A

JR1

This study

N/A

RH2

This study

N/A

RH3

This study

N/A

RMS-YM

This study

N/A

RUCH2

This study

N/A

RUCH3

This study

N/A

SCMC

This study

N/A

T91-95

This study

N/A

TE617

This study

N/A

H170

This study

N/A

HR

(Linardic et al., 2007)

N/A

COGE352

(Teicher et al., 2015)

N/A

ES1

(Teicher et al., 2015)

N/A

ES2

(Teicher et al., 2015)

N/A

ES3

(Teicher et al., 2015)

N/A
N/A

ES4

(Teicher et al., 2015)

ES6

(Teicher et al., 2015)

N/A

ES7

(Teicher et al., 2015)

N/A

EW8

(Teicher et al., 2015)

N/A

CHA59

(Teicher et al., 2015)

N/A

KHOS240S

(Teicher et al., 2015)

N/A

KHOS312H

(Teicher et al., 2015)

N/A

KHOSNP

(Teicher et al., 2015)

N/A

OHS

(Teicher et al., 2015)

N/A

HSSY11

(Teicher et al., 2015)

N/A
(Continued on next page)

Cell Reports 37, 110047, November 23, 2021 e3

ll
OPEN ACCESS

Article

Continued
Reagent or resource

Source

Identifier

SW982

(Teicher et al., 2015)

N/A

SYO1

(Teicher et al., 2015)

N/A

CHP-212

(Harenza et al., 2017)

N/A

COGN415

(Harenza et al., 2017)

N/A

COGN440

(Harenza et al., 2017)

N/A

COGN453

(Harenza et al., 2017)

N/A

COGN471

(Harenza et al., 2017)

N/A

COGN496

(Harenza et al., 2017)

N/A

COGN519

(Harenza et al., 2017)

N/A

COGN561

(Harenza et al., 2017)

N/A

COGN573

(Harenza et al., 2017)

N/A

KELLY

(Harenza et al., 2017)

N/A

NB1

(Harenza et al., 2017)

N/A

NB1643

(Harenza et al., 2017)

N/A

NBSD

(Harenza et al., 2017)

N/A

NGP

(Harenza et al., 2017)

N/A

NLF

(Harenza et al., 2017)

N/A

NMB

(Harenza et al., 2017)

N/A

SMSKAN

(Harenza et al., 2017)

N/A

SMSSAN

(Harenza et al., 2017)

N/A

COGN534

(Harenza et al., 2017)

N/A

COGN549

(Harenza et al., 2017)

N/A

FELIX

(Harenza et al., 2017)

N/A

LAN6

(Harenza et al., 2017)

N/A

NB16

(Harenza et al., 2017)

N/A

NB69

(Harenza et al., 2017)

N/A

NBLS

(Harenza et al., 2017)

N/A

https://www.jax.org/
strain/005557

Stock No: 005557

(Amir et al., 2011)

N/A

Experimental models: Organisms/strains
NOD.Cg-Prkdcscid Il2Rgtm1Wjl/SzJ (‘‘NSG’’) mice
Recombinant DNA
Lentiviral expression construct of a TCR which recognizes
the HLA*A2-restricted SLLQHLIGL peptide corresponding
to PRAME
Lentiviral expression construct of luciferase and mCherry

This study

N/A

Lentiviral expression construct of luciferase and PRAME
cDNA with C-term V5 tag

This study

N/A

This study

https://zenodo.org/record/5608456

Software and algorithms
NGS bioinformatic pipeline
R (3.3.1)

https://www.r-project.org/

CASAVA

Illumina

RRID:SCR_001802; https://support.
illumina.com/sequencing/sequencing_
software/bcl2fastqconversionsoftware.html

STAR (2.5.3a)

(Dobin et al., 2013)

https://github.com/alexdobin/STAR

GATK (3.8-1)

(McKenna et al., 2010)

https://gatk.broadinstitute.org

Tophat-Fusion (2.0.13)

(Kim and Salzberg, 2011)

https://ccb.jhu.edu/software/tophat/
fusion_index.shtml

FusionCatcher (1)

(Nicorici et al., 2014)

https://github.com/ndaniel/
fusioncatcher
(Continued on next page)
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Source

Identifier

Star Fusion (1.3.1)

(Haas et al., 2017)

N/A

ssGSEA

(Barbie et al., 2009)

https://www.genepattern.org/modules/
docs/ssGSEAProjection/4

IntegrateNeo (1.2.0)

(Zhang et al., 2017)

https://github.com/ChrisMaherLab/
INTEGRATE-Neo

EdgeR (3.7)

(Robinson et al., 2010)

https://bioconductor.org/packages/
release/bioc/html/edgeR.html

MiXCR (3.0.10)

(Bolotin et al., 2015)

https://mixcr.readthedocs.io/en/latest/

vdjTools (1.2.1)

(Shugay et al., 2015)

https://vdjtools-doc.readthedocs.io/
en/master/

pVACTools (1.5.4)

(Hundal et al., 2020)

https://pvactools.readthedocs.io/en/
latest/index.html

Superheatmap (0.1.0)

(Barter and Yu, 2018)

https://cran.r-project.org/web/
packages/superheat/index.html

KM optimization

(Wei et al., 2018)

https://zenodo.org/record/5610858

PEAKS Studio

Bioinformatics Solutions Inc.

N/A

cBioPortal

Memorial Sloan Kettering Cancer
Center, New York, NY

http://www.cbioportal.org/

VDJdb web browser

(Shugay et al., 2015)

https://vdjdb.cdr3.net/

TCRb2010

(Warren et al., 2011)

ftp://ftp.bcgsc.ca/supplementary/
TCRb2010/

Oncogenomics Expression Database

This study

https://omics-oncogenomics.ccr.cancer.
gov/cgi-bin/JK

Other

RESOURCE AVAILABILITY
Lead contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Javed
Khan (khanjav@mail.nih.gov).
Material availability
All stable reagents generated in this study will be made available from the lead contact on request after a completed materials transfer
agreement if there is potential for commercial application.
Data and code availability
d

d
d

The raw RNA-seq data analyzed in this study are available from the public databases such as Gene Expression Omnibus (GEO;
GSE89413 and GSE84629 for NBL cell lines and RD cell line respectively) or the database of Genotypes and Phenotypes
(dbGaP; phs000466 for CCSK; phs000467 for NBL; phs000468 for OS; phs000720 for RMS, phs000768 for EWS;
phs001052 for Omics study; and phs001928 for the remainder). The mass spectrometry proteomics data have been deposited
to the ProteomeXchange Consortium via the PRIDE partner repository (https://www.ebi.ac.uk/pride) with the dataset identifier
PXD017130. Accession numbers are listed in the key resources table. The expression data for this study are available at the
Oncogenomics Expression Database (https://omics-oncogenomics.ccr.cancer.gov/cgi-bin/JK).
Code of a custom bioinformatic pipeline to analyze RNA-seq data in this study is deposited at Zenodo (https://zenodo.org/
record/5608456)). An R package for Kaplan Meier optimization is available from https://zenodo.org/record/5610858.
Any additional information required to reanalyze the data reported in this study is available from the lead contact upon request.

EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human subjects
All human specimens for sequencing were obtained from patients with appropriate consent approved by the Institutional Review
Board of the participating facilities and were deemed exempt by the Office of Human Subject Research. Tumors were classified
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by local pathological review using standard histologic techniques. For PRAME immunohistochemistry validation experiments, PDXs
from diagnostic biopsies or surgical excisions were generated following written informed consent to participate in an institutional
oncology specimen repository program; approval of these consents was obtained by the internal review board from Cincinnati Children’s Hospital Medical Center (CCHMC IRB approved protocol number 2008-0021). Samples in this study were all de-identified,
therefore the age and gender of patients is not collected in this study. We performed RNA-seq on 935 samples in this study representing 657 pediatric extracranial solid tumors from 623 patients across 14 diagnoses and 147 normal human tissues.
Cell lines
We performed RNA-seq on 131 commonly used human pediatric cancer cell lines (Table S1). All cell lines used in this study have been
authenticated by either STR profiling or genotyping by sequencing.
Mouse xenograft model
Female 6-8 weeks old NSG (NOD.Cg-Prkdcscid Il2Rgtm1Wjl/SzJ) mice were used in Ewing sarcoma xenograft model to test antitumor
activities for T cells expressing a modified TCR. Animal studies were approved by the NCI Animal Research Advisory Committee and
conducted in accordance with Animal Welfare Regulations.
METHOD DETAILS
RNA sequencing
Total RNAs was isolated from freshly frozen tumors using RNeasy mini kits or AllPrep DNA/RNA mini kits (QIAGEN, Germantown,
MD). PolyA-selected or Ribozero-selected RNA libraries were prepared for RNA sequencing on Illumina HiSeq2000, 2500, and
NextSeq500 according to the manufactures protocol (Illumina, San Diego, CA). Sequencer-generated bcl files were converted to
fastq files using the bcl2fastq tool in CASAVA (Illumina, San Diego, CA) suite. Paired-end reads (100 bp for HiSeq2000, 125 bp
for HiSeq2500, and 80 bp for NextSeq500) were assessed for quality using FastQC and the average mapped unique reads in
this study is > 85 million for each sample (Table S1B). Fastq files were then mapped to GRCH37 reference genome using the
STAR/2.5.3a alignment algorithm (Dobin et al., 2013) and subsequently quantified by RSEM program (Li and Dewey, 2011) based
upon Ensembl GRCh37.75 gene annotation.
Single sample gene set enrichment analysis (ssGSEA)
Read counts for each gene between samples was normalized using TMM method implemented in edgeR (Robinson et al., 2010) and
then transformed to FPKM. This expression data was used to predict enrichment scores of twenty-four immune signatures obtained
from CIBERSORT (Newman et al., 2015) and ESTIMATE (Yoshihara et al., 2013) packages using single-sample GSEA (ssGSEA) from
GenePattern (https://www.genepattern.org/modules/docs/ssGSEAProjection/4).
Kaplan Meier optimization
We used a KM optimization procedure, a computational technique for performing optimized Kaplan-Meier survival analysis on gene
expression-derived signatures (Wei et al., 2018). Briefly, for a given gene signature, this procedure finds an optimal cutoff for stratifying patients into low-and high-risk groups that results in the maximal separation of the Kaplan-Meier survival curves and then estimates the statistical significance of this cutoff by means of the permutation test. This technique was implemented as an R package
available from https://github.com/ibkstore/kmcut. We performed the KM optimization on the osteosarcoma patient cohort where
outcome data were available.
Cancer-specific antigen analysis
Within each cancer diagnosis, gene expression of cell surface molecules, and cancer-specific transcription factors, tumor germline
antigens, were compared against normal tissue samples with the matching library prep using edgeR (Robinson et al., 2010) package.
The following criteria were used to select cancer-specific differentially expressed genes:
a)
b)
c)
d)

Differential gene expression P value (compare to all normal except testis & Ovary) % 0.00001
Differential gene expression LogFC (compare to All normal except testis & Ovary) R 4 (i.e., FC R 16-fold)
Expression in vital organs (Heart and Brain) < 1 FPKM
Expression in Tumor R 5 FPKM

T cell receptor analysis
Transcriptome sequencing reads from tumor samples were aligned to V, D, J and C genes of T cell receptors and subsequently
assembled to extract TCR sequences using MiXCR 3.0.10 (Bolotin et al., 2015). Post processing of the later repertoire data was
performed using VDJtools1.2.1 (Shugay et al., 2015). For downstream analysis, we considered only TRB-CDR3 amino acid
sequences.
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Multiplexed protein analysis
We validated our RNA-seq findings on an independent neuroblastoma tissue array (Saletta et al., 2017) using a multiplex protein
detection assay (Nanostring). After deparaffinized and rehydrated, Formalin-fixed paraffin-embedded (FFPE) tissue cores were incubated with a cocktail of 61 primary antibodies which have their own unique and UV photocleavable indexing oligo, and 2 fluorescent
markers (CD45 and Tyrosine). After overnight incubation, the slides were stained with Syto83 (nuclear DNA stain) for 15 mins before
image processing using Nanostring GeoMx Digital Spatial Profiler. Slides were loaded onto the stage of an inverted microscope and
wide field fluorescence imaging was performed with epi-illumination from visible LED light engine. 20x images from all the cores on
the TMA were stitched together to yield a high-resolution image of the tissue area of interest. Regions of interest (ROIs) within 650mM
diameter circle were selected based on the fluorescent image, and UV LED light was collimated to be reflected from the digital micromirror device (DMD) surface into the microscope objective and cleaved the oligoes from these primary antibodies. A microcapillary
tip collected cleaved oligoes into the paired wells in a 96-well plate. 2 mL of these cleaved oligoes were further hybridized with Nanostring designed Tag-set. After overnight hybridization at 65 C in a thermocycler, samples were pooled by column and processed
using the nCounter Prep Station and Digital Analyzer as per manufacturer instructions (Nanostring). Digital counts from tags corresponding to protein probes were analyzed using IgG isotype background subtraction and z-scored normalized.
Immunohistochemistry analysis
Formalin-fixed paraffin-embedded (FFPE) tissue blocks from primary bone osteosarcoma specimens were properly annotated by
pathologist, cut into 5mm sections, and mounted onto plus-charge glass slides. For each specimen staining with CD3 (clone PS1;
Leica Biosystems), CD8 (clone C8144B; Cell Marque), and CD163 (clone Novacastra10D6; Leica Biosystems) were performed according to standard protocols. IHC for PD-L1 (Spring Bioscience, clone SP142) at 0.096 mg/mL and isotype control (Spring Bioscience, clone SP137) at 1mg/mL were utilized(Sunshine et al., 2017). Whole slides scanning used Scanscope XT and digital pictures
were taken via the Indica Labs HALO digital image analysis platform.
MHC class I flow cytometry
Five osteosarcoma cell lines were stained with antibodies which is pan-reactive for MHC class I (clone W6/32, BioLegend Cat.
311405) or specific for HLA*A2 (clone BB7.2, BioLegend, Cat. 343308). Flow cytometry was performed using BD LSRFortessa
cell analyzer (BD Biosciences).
Peptide sequencing by tandem mass spectrometry
Osteosarcoma MHC class I bound peptides were isolated as described previously. Due to poor HLA*A2 IP efficiency using the serotype specific antibody (clone BB7.2), we synthesized a 3xFLAG-HLA*A2:01 lentiviral plasmid for HLA*A2:01 peptide identification.
Briefly, 2-5x108 cells were washed with ice-cold PBS and lysed in a mild lysis buffer (20mM Tris-HCL pH = 8.5, 100mM NaCl,
1 mM EDTA, 1% Triton X-100, 1:80 Halt Protease Inhibitor). Lysates were sonicated, clarified by centrifugation for 1 hour at
20,000 g at 4 C, and immunoprecipitated with anti-panMHC class I (clone W6/32, BioXcell, Cat. BE0079) or anti-FLAG (clone L5,
BioXcell, Cat. 637304) coupled protein G agarose (ThermoFisher, Cat. 22851). MHC complexes were washed and eluted in
0.15% trifluoroacetic acid in water. MHC bound peptides were isolated using C18 solid phase extraction columns (Sigma, Cat.
52601-U) and further purified by C18 spin tips (ThermoFisher, Cat. 84850) according to the manufacturer’s instructions.
Purified HLA-associated peptides were sequenced by tandem mass spectrometry (MS) using an Orbitrap Q-Exactive HF mass
spectrometer (Thermo Scientific, Waltham, MA). Briefly, peptides were separated on a reverse phase C18 Nano column (75mm 3
250mm, 2 mm particle) using a 90-minute effective gradient with 4%–35% phase B (0.1% formic acid in acetonitrile) on an Ultimate
3000 Nano liquid chromatography (Thermo Scientific, Waltham, MA). Data dependent acquisition mode was used to profile the HLA
peptidome. MS full scan range was 375-1650 m/z at resolution 120,000, and the top 15 most abundant peaks with assigned charge
state 1-4 were selected for MS/MS fragmentation using high collision dissociation (HCD) at resolution 30,000 and maximum injection
time was 200 ms, isolation window was 1.4 m/z, and dynamic exclusion was set to 20 s. The peptide sequence alignment was mapped by PEKAS studio (Tran et al., 2019) (Version 8.5, Bioinformatics Solutions Inc.) using UniProtKB human proteome sequence
database (released on Feb 7th 2017). In the PEAKS searching engine, no enzyme digestion (for natural peptides), the Orbi-Orbi
HCD fragmentation, no variable modification, and de novo sequencing (library free search) were selected. The precursor mass tolerance was 15ppm and fragment ion tolerance was 0.5Da. The false discovery rate (FDR) was estimated by decoy-fusion database and
was set to 5%. Selected peptides tandem mass spectrum was visualized and manually inspected to assure the data quality.
Modification of TCR against PRAME
We modified a TCR which recognizes the HLA*A2-restricted SLLQHLIGL peptide (Amir et al., 2011) by exchanging the constant domains of the TRAV and TRBV alleles with the murine equivalent TCR constant domains as previously described (Cohen et al., 2006) .
In addition, to increase the pairing between exogenous TCRa and TCRb, cysteine substitutions were included in the murine constant
domains of both the TRAV (T/C) and TRBV (S/C) positions 47 and 57 of the mouse constant domains, respectively (Cohen et al.,
2007). After design, codon-optimized sequences were synthesized (Genscript) and cloned downstream of the EF1a promoter. Cleavable 2A peptide sequences were used for co-expression of TRAV, TRBV and truncated EGFR.
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Generation of reporter cell lines
Stable expression of firefly luciferase and mCherry or PRAME was performed by lentiviral transduction of cells with pLenti_luciferasep2a-mCherry or pLenti_luciferase-p2a-PRAMEv5tag lentivirus. In brief, lentiviral packaging was performed in LentiX-293T (Takara
Clontech) cells by co-transfection with a luciferase transfer plasmid along with psPax2 (Addgene #12260) and pMD2.G (Addgene
#12259). HLA*A2:01 positive, PRAME negative cell lines SAOS2 and TC32 were transduced with diluted lentiviral supernatant supplemented with polybrene. Stable expression was achieved by selection for geneticin for at least 7 days.
Generation of transduced T cells
Leukapheresis samples from two healthy donors were purchased from the NIH Blood Bank (Bethesda, MD). Peripheral blood mononuclear cells (PBMC) were isolated using Histopaque (Sigma, Cat. 10771). T cells were stimulated using CD3/CD8 Dynabeads (Invitrogen, Cat. 11131D) in the presence of IL-2 (40IU, PeproTech, Cat. 200-02). After 48 hours of stimulation, T cells were transduced
with a lentiviral vector containing truncated EGFR and murPRAME-TCR. Transduction efficiency was determined 4 days after transduction by flow cytometry using a tEGFR antibody (BioLegend, Cat. 352903).
In vitro T cell cytotoxicity assays and cytokine quantification
T cells (day 9 post stimulation) were co-cultured with 5,000 target cells in 96-well plates. T cell to target cell ratio (E:T) was determined
based on transduction efficiency. After 24 hours, luciferase activity was measured using Steady-Glo Luciferase Assay (Promega, Cat.
E2520). Experiment was performed in triplicate. For U2OS cytotoxicity assays, U2OS cells were seeded in 96 well plates and allowed
to attach for 6 hours. Relative cell confluency was quantified using the xCELLigence RTCA MP instrument (ACEA biosciences, Inc.).
Media or T cells were then added to wells at an effector:tumor ratio of 3:1. Data were acquired at 15-minute increments for 30 hours
and an unpaired t test at the final time point was used for statistical analysis. For cytokine analyses, effector and target cells were cocultured at a 3:1 ratio for 18 hours. Supernatants were collected and IFNg was quantified using the V-PLEX human cytokine assay
(Meso Scale Diagnostics, Cat. K151AOH-2).
Ewing Sarcoma xenograft model with adoptive T cell transfer
Animal studies were approved by the NCI Animal Research Advisory Committee and conducted in accordance with Animal Welfare
Regulations. For xenograft studies, 2 3 106 human Ewing sarcoma cell line TC32 expressing luciferase and PRAME were injected via
tail vein into NSG mice. Tumor burden was monitored by bioluminescence imaging using the Perkin Xenogen IVIS Imaging System
with 150mg/kg D-Luciferin (PerkinElmer, Cat. 122799-5). Mice were imaged 3 hours after TC32 injection to acquire baseline luminescence and then randomized into 3 groups treated with saline (n = 8), untransduced T cells (n = 8), or murPRAME-TCR T cells (n = 8). A
total of 106 UTD or murPRAME-TCR T cells were injected via tail vein for the T cell treatment groups. Unpaired t tests were performed
at each time point comparing bioluminescence between UTD and murPRAME-TCR T cell treated mice. Kaplan Meier analysis was
performed using GraphPad PRISM using a three-way log-rank test.
QUANTIFICATION AND STATISTICAL ANALYSIS
Quantification and statistical analyses used in this study is described in detail in the previous section. Differential gene expression
was quantified using edgeR (Robinson et al., 2010) package. Log-rank tests were performed in survival analyses using GraphPad
PRISM. One-factor and two factor Cox regression analysis of overall survival was used to examine if immunological features derived
from RNA-seq data are independent of tumor metastasis, a known outcome predictor. Cell viability or growth was measured using
Steady-Glo Luciferase Assay (Promega, Cat. E2520) or relative cell confluency using the xCELLigence RTCA MP instrument (ACEA
biosciences, Inc.) respectively. Tumor burden in mice was quantified by bioluminescence imaging using the Xenogen IVIS Imaging
System (PerkinElmer). Unpaired Student’s t test was used in T cell cytotoxicity, cytokine release, and monitoring tumor burden
experiments.
ADDITIONAL RESOURCES
Accompanying this analysis, we provide a companion Oncogenomics expression database (https://omics-oncogenomics.ccr.
cancer.gov/cgi-bin/JK) for all tumors, normal tissues, and commonly utilized cell lines in the research community. The data include
gene expression derived from the RNA-seq together with outcome data for osteosarcoma and neuroblastoma with capabilities for
Kaplan–Meier survival analysis and further data exploration.
Three databases are displayed:
1. Landscape - NCI; contains all RNA-seq data across all tumors, cell lines, and normal organs.
2. Landscape Neuroblastoma TARGET; Contains RNA-seq data for all Neuroblastoma tumors and cell lines.
3. Landscape Osteosarcoma TARGET; Contains RNA-seq data for all Osteosarcoma tumors and cell lines.
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It allows users to search for individual genes of interest. The query results include heat-map and bar chart representations as well
as link-outs to more detailed annotations. As all datasets can be visualized as raw log2 (FPKM-TMM normalized) or pre-normalized
using Z-score or median centering. All query results can be downloaded as text files. Gene set enrichment analyses (GSEA) against
lists of both curated and custom gene sets can be done at 1) Individual Sample where genes are ranged by the expression of all genes
in that sample, or 2) genes ranked by correlation with that gene. Landscape Neuroblastoma TARGET and Landscape Osteosarcoma
TARGET databases contain event-free and overall survival where the user can perform Kaplan-Meier analysis using median expression level for that gene or through a KM optimization process to identify the optimal threshold for gene expression as described
above.
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